
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has demonstrated a strong financial performance with fourth-quarter gross margins expanding to an expected range of 73% to 75% and a full-year gross margin improvement to approximately 72%, indicating effective operational leverage and manufacturing efficiencies. The company reported $9.5 million in revenue for the fourth quarter, reflecting a 10% year-over-year increase, fueled by distributor-driven revenue growth and advancements in product development, particularly with DrugSorb-ATR. Additionally, the management's proactive balance sheet strategies, including a credit agreement amendment to enhance liquidity, alongside strong clinical data supporting its products, position CytoSorbents favorably for sustained growth and profitability.
Bears say
CytoSorbents Corp reported fourth quarter revenue of approximately $9.2 million, reflecting flat year-over-year performance, while full-year revenue reached around $37.0 million, indicating only 4% growth from the prior year. Management has pointed to patient imbalances in the initial U.S. market, suggesting operational challenges that could impede revenue growth. Furthermore, the company's shares are perceived to be trading at a distressed valuation, which analysts attribute to factors largely unrelated to the company's fundamental performance.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares